Page 68 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 3 Innate Immunity 53

21. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary 47. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann
angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol N Y Acad Sci 2008;1143:1–20.
2010;126:918–25. 48. Kawai T, Akira S. The role of pattern-recognition receptors in innate
22. Frank MM. Complement disorders and hereditary angioedema. J Allergy immunity: update on Toll-like receptors. Nat Immunol 2010;11:373–84.
Clin Immunol 2010;125:S262–71. 49. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by
23. Daha MR. Role of complement in innate immunity and infections. Crit Toll-like receptor 4 confers resistance to pneumococcal infection. Proc
Rev Immunol 2010;30(1):47–52. Natl Acad Sci USA 2003;100:1966–71.
24. Herbert AP, Deakin JA, Schmidt CQ, et al. Structure shows that a 50. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of
glycosaminoglycan and protein recognition site in factor H is perturbed toll-like receptors. Curr Top Microbiol Immunol 2002;270:169–84.
by age-related macular degeneration-linked single nucleotide 51. Beutler B, Jiang Z, Georgel P, et al. Genetic analysis of host resistance:
polymorphism. J Biol Chem 2007;282:18960–8. Toll-like receptor signaling and immunity at large. Annu Rev Immunol
25. Eisen DP. Mannose-binding lectin deficiency and respiratory tract 2006;24:353–89.
infection. J Innate Immun 2010;2:114–22. 52. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate
26. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol receptors in infection and immunity. Immunity 2011;34:637–50.
and sense nucleic acids and viruses via TLR7 and TLR8 receptors. 53. O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10
Immunity 2010;33:375–86. years of progress. Immunol Rev 2008;226:10–18.
27. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: 54. Tabeta K, Hoebe K, Janssen EM, et al. The Unc93b1 mutation 3d disrupts
phenotypical vs. functional differentiation. Front Immunol 2014;5:514. exogenous antigen presentation and signaling via Toll-like receptors 3, 7
28. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. and 9. Nat Immunol 2006;7:156–64.
Blood 2008;112:935–45. 55. Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for
29. Bokoch GM, Diebold B, Kim JS, et al. Emerging evidence for the interferon-alpha production by plasmacytoid dendritic cells. Nat
importance of phosphorylation in the regulation of NADPH oxidases. Immunol 2006;7:498–506.
Antioxid Redox Signal 2009;11:2429–41. 56. Doyle SL, Jefferies CA, Feighery C, et al. Signaling by Toll-like receptors 8
30. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is and 9 requires Bruton’s tyrosine kinase. J Biol Chem 2007;282:36953–60.
+
mediated through activation of proteases by K flux. Nature 57. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor
2002;416:291–7. agonist combinations synergistically trigger a T helper type 1-polarizing
31. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory program in dendritic cells. Nat Immunol 2005;6:769–76.
cytokine expression during the induction and resolution of inflammation. 58. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude
J Leukoc Biol 2010;88:1157–62. and persistence of antibody responses with innate immunity. Nature
32. Bryceson YT, Chiang SC, Darmanin S, et al. Molecular mechanisms of 2011;470:543–7.
natural killer cell activation. J Innate Immun 2011;3:216–26. 59. Palmer CD, Mancuso CJ, Weiss JP, et al. 17(R)-Resolvin D1 differentially
33. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate regulates TLR4-mediated responses of primary human macrophages to
Immun 2011;3:355–64. purified LPS and live E. coli. J Leukoc Biol 2011;90:459–70.
34. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell 60. Ignacio A, Morales CI, Camara NO, et al. Innate sensing of the gut
defects and human disease. Nat Rev Immunol 2011;11:131–42. microbiota: modulation of inflammatory and autoimmune diseases.
35. Umetsu DT, Dekruyff RH. Natural killer T cells are important in the Front Immunol 2016;7:54.
pathogenesis of asthma: the many pathways to asthma. J Allergy Clin 61. Philpott DJ, Sorbara MT, Robertson SJ, et al. NOD proteins: regulators of
Immunol 2010;125:975–9. inflammation in health and disease. Nat Rev Immunol 2014;14:9–23.
36. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection 62. Sander LE, Davis MJ, Boekschoten MV, et al. Detection of prokaryotic
due to the vaccine strain of varicella-zoster virus, in a patient with mRNA signifies microbial viability and promotes immunity. Nature
a novel deficiency in natural killer T cells. J Infect Dis 2003;188: 2011;474:385–9.
948–53. 63. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen
37. Miller LS. Toll-like receptors in skin. Adv Dermatol 2008;24:71–87. recognition and host defense. Immunity 2011;34:651–64.
38. Villablanca EJ, Mora JR. A two-step model for Langerhans cell migration 64. Gross O, Gewies A, Finger K, et al. Card9 controls a non-TLR signalling
to skin-draining LN. Eur J Immunol 2008;38:2975–80. pathway for innate anti-fungal immunity. Nature 2006;442:651–6.
39. Hayday A, Theodoridis E, Ramsburg E, et al. Intraepithelial lymphocytes: 65. Gringhuis SI, den Dunnen J, Litjens M, et al. C-type lectin DC-SIGN
exploring the Third Way in immunology. Nat Immunol 2001;2:997–1003. modulates Toll-like receptor signaling via Raf-1 kinase-dependent
40. Qiu Y, Wang W, Xiao W, et al. Role of the intestinal cytokine acetylation of transcription factor NF-kappaB. Immunity 2007;26:605–16.
microenvironment in shaping the intraepithelial lymphocyte repertoire. 66. Greaves DR, Gordon S. The macrophage scavenger receptor at 30 years of
J Leukoc Biol 2015;pii: jlb.3RU1014-465R. age: current knowledge and future challenges. J Lipid Res 2009;50:S282–6.
41. Zhang X. Regulatory functions of innate-like B cells. Cell Mol Immunol 67. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821–32.
2013;10:113–21. 68. Geyer M, Muller-Ladner U. Actual status of antiinterleukin-1 therapies in
42. Dadi S, Chhangawala S, Whitlock BM, et al. Cancer immunosurveillance rheumatic diseases. Curr Opin Rheumatol 2010;22:246–51.
by tissue-resident innate lymphoid cells and innate-like T cells. Cell 69. Alsina L, Israelsson E, Altman MC, et al. A narrow repertoire of
2016;164:365–77. transcriptional modules responsive to pyogenic bacteria is impaired in
43. Bonefeld CM, Geisler C. The role of innate lymphoid cells in healthy and patients carrying loss-of-function mutations in MYD88 or IRAK4. Nat
inflamed skin. Immunol Lett 2016;179:25–8. Immunol 2014;15:1134–42.
44. Montaldo E, Vacca P, Vitale C, et al. Human innate lymphoid cells. 70. Levy O, Netea MG. Innate immune memory: implications for
Immunol Lett 2016;179:2–8. development of pediatric immunomodulatory agents and adjuvanted
45. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and vaccines. Pediatr Res 2014;75:184–8.
regulatory cells in innate and adaptive immunity. Eur J Immunol 71. Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome
2010;40:1843–51. of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore)
46. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast 2010;89:403–25.
cells in a model of acute septic peritonitis. Nature 1996;381:75–7.